Neonatal data and biobank to understand what influences development in very preterm infants
Official title: Establishing a Neonatal Data and Biobank to Study Factors Influencing Development in Preterm Infants Born at <32 Weeks' Gestation and/or <1500 g Birth Weight
Run by University Hospital of Cologne · NCT07490912 · Data updated 2026-11-12
This project will collect clinical information and biological samples to see if early biological, clinical, and environmental factors predict short- and long-term development in infants born before 32 weeks or under 1500 g.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 18 Years |
| Sex | All |
| Enrollment | 1300 (estimated) |
| Sponsor | University Hospital of Cologne Academic / other |
| Locations | 1 site (Cologne, North Rhine-Westphalia) |
| Status | Recruiting |
| Started | March 13, 2026 |
| Main results expected | March 13, 2036 |
| Study ends | March 13, 2056 |
| Registry record updated | March 24, 2026 |
| Trial ID | NCT07490912 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are infants born before 32 weeks' gestation and/or with birth weight below 1500 g whose parents or legal guardians provide informed consent.
✕Probably not a fit
Infants born at term or above the gestational age/weight thresholds, or those without parental consent, are not eligible and would not receive direct benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Neo-Life project prospectively collects standardized clinical data and biological samples from very preterm infants (born <32 weeks gestation and/or <1500 g) at the University Hospital Cologne. Participants enter an interdisciplinary follow-up program with structured timepoints for clinical assessments and biosample collection to monitor neurological, pulmonary, cardiovascular, renal, and other outcomes. Researchers will link biological markers with clinical and environmental data to identify early risk and protective factors for later development. The resulting dataset and biobank are intended to support future research and the design of targeted interventions to reduce long-term morbidity.
Why it matters
Potential benefit: If successful, the biobank could reveal early markers and modifiable factors that enable earlier, more targeted care to improve long-term outcomes for very preterm infants.
How similar studies have gone: Similar neonatal cohorts and biobanks have identified clinical and biological factors linked to outcomes in preterm infants, although turning these findings into broadly effective treatments is still an ongoing process.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Preterm infants born \<32 weeks' gestational age and/or with a birth weight \< 1500 g * Informed consent of parents/ legal guardians Exclusion Criteria: * none
Where it's running
-
University Hospital Cologne
Cologne, North Rhine-Westphalia, Germany Recruiting
Study contacts
- Principal investigator: Angela Kribs, Apl. Prof. Dr. — University Hospital of Cologne
- Study coordinator: Charlotte S Schömig, Dr. med.
- Email: charlotte.schoemig@uk-koeln.de
- Phone: +49 221 478 85663
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Close Collaboration with Parents training to strengthen parent–staff partnership in the NICU
This pilot tests whether training NICU staff to work closely with parents improves long-term development and parent–infant interaction for very preterm infants.
-
Premature infants: trying PIOMI with mom to support feeding
Aims to see if PIOMI done with a mother’s presence and voice helps preterm babies feed better and feel more connected to mom.
-
Wireless MicroPremVitals Button Sensor for the NICU
This study tests a tiny wireless sensor system to monitor heart rate, oxygen, and temperature in extremely preterm babies in the NICU to see if it works safely without wires.
-
Gut permeability and microbiome in preterm infants
This study tests a dual sugar probe test to measure gut permeability in very preterm babies to understand their risk for serious gut disease.
-
Caffeine in pregnancy: how the mother and baby handle it during delivery
This study tests how caffeine is processed in pregnant people and how much reaches the baby when given shortly before delivery.
-
Biomarkers in infants with prior neonatal brain injury
This project will test brain activity and development using games, EEG, and parent questionnaires in infants aged 3–24 months with and without prior neonatal brain injury.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.